NextCure

Contributing Author

Recent Articles by NextCure

Apr-21	NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 NXTC -6.24% GlobeNewswire
Apr-07	NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer NXTC GlobeNewswire
Mar-31	NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 NXTC +7.88% GlobeNewswire
Mar-05	NextCure Provides Business Update and Reports Full Year 2025 Financial Results NXTC GlobeNewswire
Jan-23	NextCure Provides Business Update NXTC -5.77% GlobeNewswire
Nov-20	NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference NXTC GlobeNewswire
Nov-17	NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts NXTC GlobeNewswire
Nov-12	NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules NXTC +9.04% GlobeNewswire
Nov-05	NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results NXTC GlobeNewswire
Oct-16	NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States NXTC +27.75% GlobeNewswire
Sep-04	NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference NXTC GlobeNewswire
Aug-07	NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results NXTC GlobeNewswire
Jul-24	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta NXTC +17.30% NXTC GlobeNewswire
Jun-16	NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 NXTC -26.27% GlobeNewswire
May-29	NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 NXTC +6.41% GlobeNewswire
May-01	NextCure Provides Business Update and Reports First Quarter 2025 Financial Results NXTC -7.81% NXTC GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)